Endocrine therapy is used to treat certain types of breast cancer and is sometimes called hormone therapy or anti-hormone therapy. There are many endocrine therapy medications for example: tamoxifen, letrozole, anastrozole, exemestane, and raloxifene.
About 80% (4 out of 5) breast cancers use the hormone oestrogen to grow. Endocrine therapy works by either blocking oestrogen from getting to breast cancer cells, or by lowering the amount of oestrogen in the body.
Around 80% of individuals who are diagnosed with breast cancer will be advised to take endocrine therapy. This means that over 45,000 people will be started on endocrine therapy in the UK every year.
Endocrine therapy is a really effective medication. It can reduce the risk of cancer occurrence, or recurrence, by up to 50%. It is therefore important that we support patients to complete their course of endocrine therapy.
ETIP – Endocrine Therapy Improvement Programme
ETIP is a programme of work, developed by doctors, nurses and other health professions in Greater Manchester, to improve the support for breast cancer patients who are taking endocrine therapy. This includes patients taking endocrine medication for risk-reduction, or to treat primary or secondary breast cancer.
- Resources to improve equity of access to risk-reducing endocrine therapy for women at a high risk of developing future breast cancer
- Education for healthcare workers about endocrine therapy and how best to support patients to manage side effects
- Patient information about endocrine therapy and managing side effects
- Information about Hormone replacement Therapy (HRT) for women with a personal history of breast cancer
- Sharing patient experiences of endocrine therapy and amplifying the voices of patients
Further resources will be added to this webpage as they become available. We hope you find the resources useful.
If you have any ideas about further information or links that we should consider adding to this webpage, please do not hesitate to contact us.